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Although cervical cytology screening has decreased the incidence of cervical cancer in industrialized countries, HPV-related
cervical disease, including premalignant and malignant lesions, continues to represent a major burden on the health care system.
Some of the problems include the potential for either under- or overtreatment of women due to decreased speciﬁcity of screening
tests as well as signiﬁcant interobserver variability in the diagnosis of cervical dysplastic lesions. Although not completely
elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of
potential biomarkers for both diagnostic and prognostic use in the clinical management of these women.
1.Introduction
Cervical cancer remains a leading cause of morbidity and
mortality worldwide, with an estimated incidence of 470,000
[1]. Approximately 230,000 women die each year from
cervical cancer; over 190,000 of these women are from
developing countries in South America, sub-Saharan Africa,
and the Far East [2]. In the United States, the incidence of
invasive cervical cancer is much lower; the American Cancer
Society estimated that in 2010, there were approximately
12,200 new cases, with the number of estimated deaths at
4,210 [3]. The diﬀerences in incidence are attributed mainly
totheutilizationofcytologicalscreeninginnumerousindus-
trialized countries during the latter half of the 20th century
[4]. In the US, the main burden of cervical disease manifests
as a much higher number of premalignant lesions, including
low grade cervical intraepithelial neoplasia (CIN1) (over 1.4
million new cases) and high grade lesions (CIN2/3) (330,000
new cases) [5]. Overall, the clinical management of patients
with cervical premalignant and malignant lesions represents
a signiﬁcant burden on the health care system. Although
improved methods are needed to improve the accuracy of
cervicalcancerscreening,itisalsoimportanttoconsiderthat
the vast majority of cervical cancer deaths worldwide occur
in women that have never been screened.
The association between cervical premalignant and
malignant epithelial lesions and human papillomaviruses
(HPV) has been well established [6, 7]. There are over
100 deﬁned HPV types, and these have been subdivided
intohigh-risk(HR-HPV)andlow-risk(LR-HPV)categories,
based on their association with cervical cancer [8, 9].
Although the majority of women with HR-HPV infections
have only transient infections that do not lead to malignant
transformation of the cervical mucosa, HR-HPV is the
etiologic agent of virtually all cases of cervical cancer. Dunne
et al. found that while the overall prevalence of HPV
infection (including both low-risk and high-risk types) in
US women between the ages of 14 and 59 years of age was
26.8% (n = 1921), the prevalence of high risk HPVs was
15.2%. Furthermore, there was a marked peak in HR-HPV
infection in women between the ages of 20 and 24, with a
prevalence of 29% [10]. The vast majority of HPV infections
(up to 90%) regress spontaneously, without treatment, after
a few months [11, 12]. If the viral infection persists, however,
the risk of developing a precancerous lesion increases as well
as the risk of developing an invasive carcinoma [12, 13]. This
underscores the importance of accurate diagnosis as well as
identiﬁcation of those lesions at highest risk for progression.
Histological examination of colposcopy-guided biopsies
is still considered the “gold standard” in the assessment of2 Journal of Oncology
cervical lesions; however, the histologic assessment of these
lesions is limited to the interpretation of the morphology,
withlittletonoinformationregardingtheriskofpersistence,
progression, or regression. In addition, histologic assessment
of cervical lesions is complicated by interobserver variability
[14]. The main interpretive categories include distinguishing
normal from dysplasia (CIN) of any grade and low-grade
(CIN1) lesions from high-grade (CIN2/3) lesions. Errors in
histologic diagnosis lead to either overtreatment of patients
who will not beneﬁt from intervention or, conversely, under-
treatment of patients with clinically signiﬁcant high-grade
lesions that received false negative diagnoses. The HPV life
cycle and molecular events leading to cellular transforma-
tion, while not completely elucidated, have provided insight
into potential biomarkers that can be used as adjunctive tests
to improve diagnostic accuracy of cervical lesions as well as,
identify those patients at risk for progression to cancer. This
paper focuses on those biomarkers that appear to be most
relevant in the clinical management of patients with HPV-
related cervical disease.
2. HPVReview
Human papillomaviruses (HPVs) are a diverse group of
viruses (numbering more than 100) that can infect numer-
ous epithelial sites and cause a variety of epithelial lesions,
including common warts, verrucas, laryngeal papillomas,
and genital condylomata, depending on the type of HPV
[15]. The diﬀerent types that infect the female genital tract
have been divided into high-risk types (HR-HPV, including
types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,
and 68) and low-risk types (LR-HPV, including types 6, 11,
40, 42, 54, and 57). The LR-HPVs are associated with benign
exophytic genital warts (condylomata acuminata) and are
rarely associated with high-grade squamous intraepithelial
lesions (HSILs) or invasive squamous cancers. Conversely,
HR-HPVs, especially HPV-16, the most prevalent virus
infecting the cervix, are associated with the entire spectrum
of CIN lesions as well as, invasive squamous carcinomas.
Recent studies have demonstrated that HR-HPV types
account for almost 90% of all cervical infections [16].
The HPV genome consists of a double-stranded circular
genome that includes early and late open reading frames
(ORFs). The early ORFs E1 through E7 encode proteins that
are involved in the regulation of DNA replication and cell
proliferation, while the late ORFs L1 and L2 encode the two
viral capsid proteins [15]. CIN1 lesions reﬂect high levels of
HPV episomal replication, the so-called “productive infec-
tions.” In these cases, the E1/E2 open reading frames serve as
negative regulators of E6 and E7. In CIN 2 or more severe
lesions (CIN2+), however, arrested squamous maturation
no longer supports eﬀective HPV DNA replication, and the
copy number of HPV DNA is generally low. In these lesions,
a transforming event, often associated with disruption of
E1/E2 by the integration of the HPV genome into the host
genome, results in the unregulated expression of E6 and
E7. Overexpression of E6 promotes cell-cycle progression
by promoting degradation of p53, allowing cell-cycle pro-
gression even in the face of genomic damage, while E7
promotes the degradation of Rb, resulting in the release
of transcription factor E2F and cell-cycle progression. The
degradation of Rb also results in the hypomethylation of the
p16INK4a promoter, enabling high-level overexpression of
p16INK4a [17]. The identiﬁcation of these major components
in HPV-mediated oncogenesis provides potential targets for
clinically relevant biomarkers.
3.HPV DNA
Themostwidelyusedandextensivelyinvestigatedbiomarker
in the management of cervical disease is HPV DNA testing.
There are a wide range of HPV detection techniques, includ-
ing in situ hybridization, and genotyping assays, including
molecular ampliﬁcation assays with or without genotyping
[17]. The Digene HPV test, which uses Hybrid Capture 2
(HC2) technology, and the Cervista HPV HR assay are the
only methods that currently have FDA approval for diagnos-
tic testing in the United States.
The Digene HPV Test (Qiagen, Valencia, Calif, USA)
was the ﬁrst HPV test that was licensed by the FDA
(United States Food and Drug Administration). This test is
a solution-phase hybridization assay that uses RNA probes
complementary to HPV DNA, resulting in signal ampliﬁ-
cation. This test detects the presence of 13 HR-HPV types
(16/18/31/33/35/39/45/51/52/56/58/59/68) or 5 low-risk
types (6, 11, 42, 43, and 44). The assay is usually performed
using only the HR-HPV probe set, since LR-HPV is not
clinically signiﬁcant. In the ASCUS-LSIL Triage Study
(ALTS), HC2 was shown to provide more eﬀective triage
of ASCUS cytology than a repeat cytology examination [5].
Other randomized large studies have reported that 50% to
70% more precancerous lesions may be diagnosed when
HPV testing is incorporated in primary screening [18–
20]. Another advantage is that because a negative result
excludes the risk of HPV-related disease in subsequent years,
screening intervals may safely be increased to 3 to 5 years
in those patients with a negative result. Other advantages
include good interlaboratory reproducibility [21]a n de a s e
of use. One of the disadvantages is that this assay does not
produce information on individual HPV types; instead, the
presence of at least one of the high-risk or low-risk types
is reported. This is a signiﬁcant limitation, since persistent
infection with HR-HPV is a risk factor for progression to
cervical cancer and with the advent of HPV vaccines, it is
increasingly relevant to perform HPV genotyping to identify
oncogenic HPV vaccine types [22]. HPV genotyping is of
clinical interest, since the risk of developing a precancerous
lesion is between 10%, and 15% with HPV types 16 and
18, and below 3% for all other high-risk types combined.
Genotyping information could provide more information
regardingrisk-stratiﬁcationaswellaspersistenceofinfection
[23].
The Cervista HPV HR test (Hologic, Bedford, Mass,
USA) detects the presence of 14 HPV types designated
as high risk by the International Agency for Research on
Cancer (IARC), consisting of 16/18/31/33/35/39/45/51/52/Journal of Oncology 3
56/58/59/66/68.ThisassayutilizesInvaderchemistry,asignal
ampliﬁcation method for the detection of speciﬁc nucleic
acid sequences. This method comprises two isothermal
reactions: a primary reaction on the targeted DNA sequence
and a secondary reaction that produces a ﬂuorescent signal.
In a comparison between the Digene and Cervista assays, the
Cervista assay demonstrated 100% sensitivity in the detec-
tion of CIN 3 or worse and 98% sensitivity for the detection
of CIN 2 or worse [24]. After adjustments to compensate
for potential bias related to availability of biopsy histologic
diagnoses, the expected clinical performance of the HPV
HR test is 95.49% sensitivity, speciﬁcity 63.3%, PPV 10.1%,
and NPV 99.7%. In this study, the authors reported that
the Cervista assay had a lower false-positive rate compared
to the Digene assay (attributed to cross-reactivity with low-
risk HPV types). Some other strengths of the Cervista
assay include an internal positive control to determine the
presence of suﬃcient DNA and the presence of potentially
interferingsubstancesandrequiringasmallersamplevolume
compared to other assays. However, IARC determined that
there is limited evidence to conclude HPV 66 is carcinogenic;
although the prevalence of HPV 66 in women is low, this
reclassiﬁcation may have a marginal impact on the false-
positivity rate [25]. Also, similar to the Digene assay, infor-
mation regarding individual HPV types is not provided. To
address this, a DNA-based genotyping assay was developed
as well.
The Cervista HPV 16/18 test (Hologic, Bedford, Mass,
USA) has been approved by the FDA for use in conjunction
with the Cervista HPV HR test. This test utilizes the same
Invader chemistry used by the HPV HR test in the analysis
of cervical cytology specimens. Clinical validation and
analytical performance studies report that the Cervista HPV
16/18 genotyping test demonstrated a high degree of ana-
lytical sensitivity, and speciﬁcity, and performed as expected
in women with ASC-US cytology who were positive for HR
HPV [25, 26]. These studies support the utilization of the
genotyping test in the proper clinical context.
The polymerase chain reaction (PCR) method of detect-
ing HPV enables the sensitive ampliﬁcation of even small
amounts of HPV DNA, enabling the evaluation of extracts of
formalin-ﬁxed histologic sections which generally yield frag-
mented DNA [17]. Brieﬂy, the two major types of available
PCR assays are type-speciﬁc and consensus sequence assays.
The type-speciﬁc assays amplify a single HPV genotype,
necessitatingmultipleseparatePCRassaysandincreasingthe
cost for genotyping each sample. The consensus assays detect
a wide range of HPV types, most commonly using primers
that target the L1 region. Once the sample is ampliﬁed, there
are a number of methods that may be used to determine the
speciﬁc type of HPV, including nucleic acid hybridization,
restriction fragment length polymorphism, and sequencing.
There are, however, cost and other considerations currently
that limit clinical application.
Overall,HPVDNAtestinghasasensitivityabove90%for
the detection of underlying CIN2+ lesions but has generally
poor speciﬁcity for underlying clinically signiﬁcant lesions,
because most positive cases represent only transient infec-
tions rather than providing evidence of cervical mucosal
transformation [27]. As a result, HPV testing is useful for
the triage of women with ASCUS cytology but is generally
not used for the triage of women under the age of 30 with
other cytologic diagnostic testresults. HPV testing in women
over the age of 30, in combination with liquid-based cervical
cytology, can, however, be used to increase the screening
interval in women over age 30 due to the high negative
predictive value of HPV testing. Although HPV genotyping
provides more information regarding a patient’s risk for pro-
gression, individual typing assays are not commonly used for
routine cervical cancer screening.
4.HPVViralLoad
Viral load may be a useful marker in predicting the risk
of progression. High viral load is often considered to be
indicative of persistent infection and progression, while low
viral load has been interpreted to reﬂect HPV viral clearance.
A fundamental pitfall of this concept, however, is that CIN1
lesions reﬂect productive infections and may have thousands
of viral copies/cell in upper layers of the cervical mucosa, but
CIN2/3 and SCC lesions may have as low as a single copy of
viral DNA/cell (commonly integrated into the host genome
but not supporting viral replication) [28]. Thus, there is at
least a theoretically increased risk of false negative HPV test
results in high-grade lesions compared to low grade lesions,
unless the high grade lesional cell sample also includes cells
that are derived from a coexisting low-grade productive
infection. HPV viral copy number may be determined
using PCR assays that target type-speciﬁc HPV DNA and
normalize to the total human DNA present [29]. In a study
byCarcopinoetal.,HPV16and18viralloadswererelatedto
the severity of the cervical lesion [30] although as suggested
above, these results may have been impacted by the presence
of cells that were actually derived from low-grade lesions.
5.HPV mRNA
AssaysforthedetectionofE6/E7mRNAhavebeendeveloped
based on the concept that E6/E7 expression results in a
transforming event with unregulated cell-cycle progression
due to degradation of p53 and Rb [31]. The PreTect
HPV-Proofer assay (NorChip AS, Klokkarstua Norway) is a
commerciallyavailableassay(inEuropeonly)todetectE6/E7
mRNA from ﬁve HR-HPV types (16, 18, 31, 33, and 45)
[32]. A positive HPV-Proofer result is indicative of E6/E7
integration and identiﬁes a high risk of persistent infection.
In a study by Molden et al., a comparison of HPV DNA
and mRNA was performed on women with an initial
diagnosis of ASCUS or LSIL on cervical cytology, with a 2-
year follow-up period [33]. In this study, women with a pos-
itive HPV-Proofer assay were approximately 70 times more
likely to be diagnosed with CIN2 or greater than women
who tested negative. Consensus PCR testing for HPV was
also performed; women who tested positive were 6 times
more likely to be diagnosed with CIN2 or greater than
women who tested negative. These results suggest that the
HPV-Proofer assay is as sensitive but is more speciﬁc than
HPVPCRforthedetectionof underlying high-gradelesions.4 Journal of Oncology
The APTIMA HPV assay is another commercially avail-
able test for mRNA detection (Gen-Probe, San Diego, Calif,
USA). The APTIMA HPV assay detects mRNA from 14 HR-
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68) using liquid-based cervical cytology specimens.
The assay involves target capture, target ampliﬁcation, and
the detection of the ampliﬁcation products. This assay is
currently in clinical trials, with a focus on the identiﬁcation
of women that are at high risk for persistent infection.
6.HPVL1 CapsidProtein
The L1 capsid protein represents approximately 90% of
the total protein on the virus surface and is generally
detectable during the reproductive phase of HPV infection.
The L1 protein is abundant in productive infections [34, 35];
conversely, it is found only in rare cases of CIN3, and it is not
produced in carcinomas [34]. In general, CIN2/3 lesions are
unlikely to support productive HPV infection, because viral
maturation depends on squamous maturation that, by deﬁ-
nition, is arrested in CIN2/3. There have been a few studies
evaluating the prognostic signiﬁcance of L1 status; although
the studies are relatively small, it has been suggested that
L1 status may have utility in the prediction of disease pro-
gression [35–37] .Ar e c e n ts t u d yb yG a l g a n oe ta l . ,h o w e v e r ,
found that L1 was neither sensitive nor speciﬁc for the
detection of CIN2/3 lesions [38].
7. p16INK4a andKi-67
p16INK4a is a tumor-suppressor protein and cyclin-depend-
ent kinase (cdk) inhibitor that blocks cdk4- and cdk6-
mediated pRb phosphorylation to inhibit E2F-dependent
transcription and cell-cycle progression [39]. In most cer-
vical carcinomas, the functional inactivation of pRb by
HPV E7 results in the overexpression of p16INK4a and the
accumulation of the protein in cells. p16INK4a is thus a
surrogate marker of HPV E7-mediated pRb catabolism,
providing evidence of transformation of the cervical mucosa
[40, 41]. p16INK4a has been successfully deployed for the
classiﬁcation of HPV-related disease for several reasons [42]:
(1) the expression of p16INK4a is directly linked to the
HPV oncogenic action, since continuous expression of E7
is necessary to maintain the malignant phenotype, (2) the
expression of p16INK4a is independent of the HPV type, and
therefore, genotyping does not need to be performed, and
(3) the expression of p16INK4a by cycling cells is a speciﬁc
marker of HPV-E7 overexpression or other events that
inactivate Rb [43]. Immunohistochemical analysis has de-
monstrated that diﬀuse staining for p16INK4a is present in
almostallcasesofCIN2,CIN3,andsquamouscellcarcinoma
(as well as in endocervical glandular neoplasia); however,
it is rarely detected in benign squamous mucosa or CIN1
lesions associated with LR-HPV [40, 41]. One limitation of
the analysis of p16INK4a as a marker of cervical neoplasia
is that focal and occasionally diﬀuse expression can also
be observed in benign endocervical intercalated colum-
nar cells, in tuboendometrial metaplasia, and in cervical
endometriosis[44].Theexpressionofp16INK4a inthesecells,
however, denotes no premalignant potential. Focal staining
can also be detected in the lower third of some CIN1 lesions
and in the upper third of the epithelium in a few cases
of squamous metaplasia. The diﬀuse pattern of p16INK4a
expression within the lower third of the squamous mucosa,
however, is highly speciﬁc for CIN1+ lesions, and diﬀuse
expression in glandular epithelial cells usually reﬂects endo-
cervical glandular neoplasia (lesions with some but not all
features of AIS), AIS, or invasive adenocarcinoma.
For cervical tissue punch and cone biopsies, immuno-
histochemistry for p16INK4a has been reported to reduce
interobserver disagreement when compared with diagnosis
of H&E stained sections [45–47]. In one study, 496 cervical
histology H&E-stained slides (each representing an indepen-
dent case, either punch or cone biopsy) were evaluated by
6 pathologists. Interobserver agreement for punch biopsies
was moderate (mean κ = 0.49) and substantial for cone
biopsies (mean κ = 0.63) [45]. The addition of p16INK4a -
immunostained, consecutive slides read together with the
H&E-stained slides signiﬁcantly improved the interobserver
agreement for the interpretation of both punch and cone
biopsies. For the punch biopsies, the κ value increased from
0.49 (moderate agreement) to 0.64 (substantial agreement),
and the κ value for the cone biopsies increased from 0.64 to
0.70. A subsequent study by Bergeron et al. [48] addressed
the utility of p16INK4a testing for both increasing interob-
server agreement as well as increasing diagnostic accuracy.
In this study, H&E-stained slides from 500 cases (comprising
cervical punch and cone biopsies) were interpreted by twelve
community pathologists. These interpretations were com-
pared to the “gold standard” diagnoses established by three
expert gynecologic pathologists. After a “washout” period
of at least four weeks, the same H&E-stained slides were
reassessed by the twelve pathologists, but this time in con-
junction with p16INK4a -immunostained matched slides. The
pathologists were blinded to their original diagnoses as well
as the gold standard diagnoses. Overall, diagnostic accuracy
forhigh-gradeCINwassigniﬁcantlyimprovedwiththeaddi-
tionofp16INK4a -immunostainedslides.Themeansensitivity
increased from 0.77 to 0.87 (an increase in sensitivity of
13%). The number of missed high-grade CIN cases was
reduced by 45%. The number of cases with a gold standard
diagnosisofCIN3thatweremissedbythecommunity-based
pathologists was decreased by 60%. Importantly, this gain in
sensitivity was not associated with a relevant loss in speci-
ﬁcity. Also, the interobserver agreement of the community-
based pathologists for categorizing lesions as high-grade
CIN versus CIN 1 or negative for dysplasia signiﬁcantly
improved with the addition of the p16INK4a -immunostained
slides, with a κ coeﬃcient of 0.749 (for H&E stained slides
only, the κ coeﬃcient was 0.566). Also demonstrated in this
study was the relative ease with which accurate, reproducible
interpretation of p16INK4a -immunostained slides can be
implemented into clinical practice [48]. In addition to
improving diagnostic accuracy and reproducibility, the use
of p16INK4a immunohistochemistry may help in identifying
CIN1 lesions that are associated with HR-HPV types; these
lesions are at an increased risk for progression to high-grade
dysplasia or carcinoma [49].Journal of Oncology 5
p16INK4a has also recently emerged as a sensitive and
speciﬁc diagnostic adjunct for underlying CIN2+ lesions in
cervical cytology specimens [50, 51]. Most studies that have
evaluated the use of p16INK4a as an immunocytochemical
diagnostic adjunct have relied on the use of scoring criteria
that depend on both the morphologic interpretation of
p16INK4a positive cells and on the use of quantitative thresh-
olds to establish positive test results [50]. Samarawardana
et al. established rigorous criteria for scoring p16INK4a test
resultsthatwasassociatedwithdecreasedsensitivityandneg-
ative predictive value but improved speciﬁcity and positive
predictive value compared with most of the previous reports
of p16INK4a test performance. Denton et al. used a diﬀerent
scoring system in the evaluation of p16INK4a test results and
also demonstrated that the use of p16INK4a immunostaining
on cytology provides signiﬁcantly better speciﬁcity than HR-
HPV for the triage of ASC-US and LSIL cytology cases
[51]. It is important to emphasize that the primary value of
p16INK4a and other cervical cancer biomarkers is to improve
test speciﬁcity rather than sensitivity relative to HPV testing.
Ki-67 is a proliferation marker that is conﬁned to the
parabasal cell layer of normal stratiﬁed squamous mucosa
but shows expression in the stratiﬁed squamous epithelium
in CIN lesions in correlation with the extent of disordered
maturation. Although Ki-67 has been used as a diagnostic
adjunct for the classiﬁcation of cervical tissue specimens
[52, 53], the expression of Ki-67 alone does not discriminate
HPV-mediated dysplasia versus benign proliferating cells in
benign reactive processes, which limits its use in cytologic
specimens as a speciﬁc marker of underlying CIN or
glandular neoplasia. Recent large-scale studies from Europe
and pilot studies from the US, however, show that a dual
stain approach for p16INK4a and Mib-1, (using the CINtec
Plus kit from MTM Laboratories, Westborough, Mass, USA)
can be used to score cases positive on the basis of a single
dual stained epithelial cell, independent of cell morphology,
resulting in sensitivity that rivals HPV testing but with
speciﬁcity that is greater than that provided by HR-HPV
testing [54–60].
8. DNA Aneuploidy
HPV infection may lead to DNA hypermethylation (dis-
cussed below), disruption of the normal cell cycle, and
chromosomal aberrations, all of which may lead to changes
in DNA content. Studies using DNA-cytometry of Feulgen-
stained cytology material to assess ploidy have demonstrated
signiﬁcant diﬀerences in aneuploidy between HSILs and
LSILs: 79% aneuploid versus 4%, respectively [61]. Subse-
quent studies have reported a strong association between
highly aneuploid squamous cells and HR-HPV [62]a sw e l l
as a positive predictive value of 81.8% for CIN 2 for 9c cells
[63]. A prospective study by Grote et al. demonstrated a
signiﬁcant increase in DNA aneuploidy in cervical cytology
material from patients with CIN 1 (54%) and CIN 2 (64.3%)
to CIN 3 or greater (83.3%) on subsequent biopsies [64].
In a preliminary retrospective study assessing the utility of
DNA ploidy in the management of ASC cytology specimens,
Lorenzato et al. suggest that the combined use of HR-HPV
testing and DNA ploidy measurement on ASCUS cytology
specimens may improve the triage of women who have
to undergo colposcopy as well as identify patients with a
diagnosis of ASC-H at higher risk for CIN 2 or greater
lesions [65]. DNA image cytometry has become increas-
ingly standardized and represents an objective and highly
reproducible diagnostic procedure [64].
9.ProExCTest
The ProExC test (BD TriPath Imaging, Burlington, NC,
USA) is a recently developed immunocytochemical assay
for the detection of minichromosome maintenance proteins
(MCMs) and in previous formulations, Topoisomerase 2α,
in cervical cytology slides, as a marker of aberrant S-phase
induction and underlying high-grade dysplasia. MCMs are
membersoftheDNAlicensingfactorfamilythatarerequired
for the origination of DNA replication and are overexpressed
in cervical high-grade dysplasia and carcinoma [66–68].
Preliminary studies demonstrated that the ProExC test is
consistently positive in HSILs and negative in normal cyto-
logic specimens [69, 70] but to date, the ProExC assay has
not come into widespread utilization as a diagnostic adjunct
for cervical cytology due at least in part to expression of
MCMs in some benign cycling squamous and glandular cells
[71,72].Furtherconﬁrmationoftheperformanceofthistest
as a diagnostic adjunct for cervical cytology will depend on
the results of large-scale trials including biopsy correlation
and clinical outcome correlation.
10.Methylation Markers
As part of the search for novel and relevant biomarkers in
cervical disease, attention has been focused on methylated
genes. Of particular interest is that p16INK4a has been found
to be inactivated in numerous cancers due to mutations and
epigenetic alterations (patterns of altered gene expression
mediated by mechanisms that do not aﬀect the primary
DNA sequence) [73]. Methylation of a CpG island within the
p16INK4a exon1α has been associated with a variety of malig-
nant tumors, such as nonsmall cell lung cancer, colorectal
cancer or pancreatic cancer [74–76]. Several groups have
analyzed cervical cancers for p16 exon1α methylation, with
frequencies ranging from 19% to 61% [77–84]; however,
most of these studies reported methylation data without
conﬁrmation of the expression level. Nehls et al. performed a
detailed analysis of p16INK4a exon1α methylation, with com-
parisontop16INK4a expression,usingbothcelllinesandclin-
ical samples [85]. They found composite or complete methy-
lation of p16INK4a exon1α without any inﬂuence on p16INK4a
expression and concluded that methylation in this region
does not suppress p16INK4a expression. Wentzensen et al.
recently published a systematic literature review of studies
analyzing the utility of methylation markers in cervical
cancer [86]. They identiﬁed 51 studies analyzing 68 diﬀerent
genesformethylation acrossallstagesofcervicalcarcinogen-
esis. This group found that the published data was highly6 Journal of Oncology
heterogeneous; for 7 genes, there was a reported range of
methylation frequencies in cervical cancers of greater than
60% between studies. They did identify 3 markers, DAPK1,
CADM1, and RARB, which showed elevated methylation in
cervical cancers consistently across studies. Thus, based on
these ﬁndings, no methylation markers can yet be utilized
in cervical cancer screening or triage settings. Similar to
other diagnostic molecular approaches, large, well-powered
epidemiologic studies are still needed to identify and validate
candidate methylation markers of cervical neoplasia.
11.FISH
Fluorescent in situ hybridization (FISH) technology has
increasingly been recognized as a valuable tool to evaluate
cervical dysplasia [87, 88]. Studies have demonstrated that
oneofthemostconsistentchromosomalabnormalitiesiden-
tiﬁed in cervical carcinoma is gain of chromosome arm 3q,
which is detected in approximately 70% of cervical carcino-
mas[89,90]. These extra copies resultin a gainof the human
telomerase RNA gene (TERC) located in the 3q26 region.
The gene product, telomerase, is involved in chromosome
maintenance by providing telomere stability and regulating
telomere length. In a study by Caraway et al., FISH analysis
for gain of chromosome 3q was performed on cervicovagi-
nal liquid-based preparations, and results were compared
withcytologicdiagnosisandconcurrent/subsequentbiopsies
[91]. Patients with HSIL or squamous cell carcinoma cy-
tologic diagnoses had signiﬁcantly higher percentages of
cells with 3q26 gain than patients with negative or ASC-US
diagnoses. Seppo et al. demonstrated that a fully automated
FISH scoring system can detect gain of 3q in liquid cytology
samples [92]. Another study evaluated HPV DNA and
telomerase using a diﬀerent assay (telomeric repeat ampli-
ﬁcation protocol, TRAP) as diagnostic adjuncts in cervical
cytology specimens [93]. Interestingly, telomerase showed
a low sensitivity (29.9%) for biopsy-conﬁrmed CIN 2/3;
the study concluded that the TRAP assay for telomerase is
unlikely to be used as a diagnostic adjunct. FISH analysis for
3q appears to hold more promise as a useful biomarker.
12. Conclusion
Despite the tremendous progress that has been achieved
in the screening and management of women with HPV-
related cervical disease, there is still a need for clinically
robust biomarkers to further reﬁne the screening, triage, and
management of women. In this paper, we focused on those
biomarkersthathavethegreatestutilityintheclinicalsetting,
such as those that will increase screening and diagnostic
accuracy of cervical specimens and tissue biopsies, and we
provide information regarding the risk for progression to a
more severe lesion. Examples of these include HPV DNA
testing for the eﬀective triage of women with abnormal cer-
vical cytology, and the use of p16INK4a immunohistochem-
istry to increase diagnostic accuracy of dysplastic lesions.
Merely identifying the presence of HPV infection is not
suﬃcient, as multiple studies have demonstrated. We expect
that in the future, in addition to cervical cytology, more
advanced techniques, including HPV genotyping, will be
used to identify and triage those women most likely to
harbor a clinically signiﬁcant cervical lesion. Assays for HPV
viral load and mRNA detection may be useful in both the
triage of abnormal cervical cytology, and detecting persistent
infection, which is associated with an increased risk for
disease progression. We also reviewed new applications of
technologies such as FISH and the detection of DNA methy-
lation; although their clinical utility is still under investiga-
tion, they have the potential to provide valuable information
in the identiﬁcation of disease, risk of disease progression,
and clinical management of patients. Although cervical can-
cer biomarkers will provide increasingly detailed and impor-
tant information in countries that have organized screen-
ing programs, their utility will depend on the resolution
of social and economic factors that have precluded the uti-
lization of cervical cancer screening programs in developing
nations.
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